In conclusion, our comprehensive in vitro and in vivo studies employing gain-of-function, loss-of-function, and combination therapy approaches have demonstrated the critical roles of the ALG3-FOXD1 axis in mitophagy, a process that contributes to NPC growth and gemcitabine resistance. This evidence concerns the gene ALG3 and nasopharyngeal carcinoma.